Carregant...

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Rheumatol
Autors principals: Fleischmann, Roy, Schiff, Michael, van der Heijde, Désirée, Ramos‐Remus, Cesar, Spindler, Alberto, Stanislav, Marina, Zerbini, Cristiano A. F., Gurbuz, Sirel, Dickson, Christina, de Bono, Stephanie, Schlichting, Douglas, Beattie, Scott, Kuo, Wen‐Ling, Rooney, Terence, Macias, William, Takeuchi, Tsutomu
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347954/
https://ncbi.nlm.nih.gov/pubmed/27723271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39953
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!